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Abstract 
The human immune system consists of innate and adaptive mechanisms of defence that 
protect the host from harmful substances.  Cytokines and other immune components play an 
important role in the induction and regulation of these defence mechanisms.  Despite these 
mechanisms, sometimes pathogens still manage to evade the immune system causing disease; 
or allergens result in hypersensitive reactions; or the immune system becomes overly 
sensitive and starts attacking the “self”.  Irrespective of the cause, despite its best efforts, the 
immune system sometimes needs help regulating its defences. 
Artemisia afra is an indigenous member of the daisy or Asteraceae family.  It is one of the 
oldest and most common plants used as a traditional medicine in South Africa.  Because of 
the great diversity of ailments traditionally treated with Artemisia afra, it is considered a 
“cure-all”.  The aerial parts contain various phenolic compounds that have anti-bacterial and 
anti-fungal activity.  This helps to explain its popularity in treating bacterial infections such 
as sore throats, ear infections and various bronchial diseases.  Other traditional uses include 
viral infections such as measles and influenza, and parasitic infections such as malaria and 
intestinal parasites.  Non-pathogenic conditions traditionally treated with Artemisia afra 
include diabetes mellitus, gout and neuraligia, autoimmune conditions like rheumatoid 
arthritis and allergic conditions such as asthma.  Due to this wide range of traditional 
indications, Artemisia afra is thought to have immune regulating effects. 
Herbal medications are becoming increasingly popular with the general public.  Knowledge 
regarding indigenous medicines is very limited, while the need for such knowledge is 
becoming more essential.  It is estimated that in Africa approximately 80 % of people rely on 
herbal medicine for primary health care.  Most literature sources focus on the study of 
European herbs and medical practitioners are not well equipped to guide the public on issues 
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relating to herbal medicines.  Adverse and side effects of herbs become common when the 
herb is taken incorrectly or together with certain medications.  Despite the wide variety of 
conditions traditionally treated with Artemisia afra, limited literature exists regarding the bio-
activities on the species, and no immune studies have been done until now.  The aim of this 
study was to use human whole blood cultures to examine Artemisia afra’s 
immunomodulating effects in vito.    
A 20 % (w/v) Artemisia afra extract was prepared using 94.4 % ethanol and milled aerial 
herb organs.  The extract was air dried and re-suspended in DMSO to obtain a 50 % (wet leaf 
w/v) extract.  Blood was collected from healthy male volunteers and diluted with RPMI-
1640.  To measure inflammatory activity and cytotoxicity, stimulated blood contained 1 
volume of 10 μg/ml LPS in DMSO, 10 volumes of blood and 89 volumes of RMPI-1640.  
Blood (200 μl/well) was added to various concentrations of Artemisia afra.  This was 
incubated at 37 ºC for 24 hours.  For cell-mediated and humoral immunity, stimulated blood 
contained 10 volumes of blood and 89 volumes of RPMI-1640 medium and 1 volume of 1.6 
mg/ml PHA in RPMI-1640 and incubated for 48 hours.  An LDH assay was used to analyse 
the herb for cytotoxicity and various ELISAs for cytokine analysis.  IL-6 was used as a 
biomarker for inflammatory activity, IL-10 for humoral immunity and IFN-γ for cell-
mediated immunity.   Results were statistically analysed using ANOVA tests. 
Results showed that Artemisia afra was significantly cytotoxic (P<0.050) at 5 000 μg/ml.  IL-
10 production was significantly suppressed (P<0.001).  This result indicates down regulation 
of the Th2 pathways, coinciding with its traditional use in allergic conditions.    IFN-γ 
production was also significantly suppressed (P<0.001).  This implies that although no direct 
immune defences are offered against bacterial, viral and parasitic infections, they may still 
provide symptomatic relief by decreasing fever as it also significanlty decreased IL-6 release 
(P<0.001).  Direct anti-microbial effects of Artemisia afra on various pathogenic agensts 
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such as Plasmodium and Influenza were not tested.  The decrease of IL-6 production occurred 
at high concentrations (1 666 and 5 000 µg/ml).  This demonstrates a potential ability to 
reduce the effects of conditions associated with abnormally high levels of IL-6 such as 
rheumatoid arthritis and arteriosclerosis.   
This study shows that herbs can be effectively screened for potiential bio-activity using in 
vitro methods.  Further studies will be needed to better explore Artemisia afra’s effect on  
immunoregulation, particularly long term effects of the herb on the immune system and its 
effect on other disease states.   
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Chapter 1:  The bio-activities of Artemisia afra 
1.1  Introduction 
Artemisia afra (Asteraceae/Daisy) is one of the oldest and best known of South Africa‟s 
indigenous medicines. The plant may also be found in Eastern parts of Africa and is used as a 
medicine in Ethiopia (van Wyk and Gericke, 2005; Van Wyk, 2008).  Wormwood, the 
common name, is derived from the Old English word „wermode‟, meaning “mind preserver” 
(Mars, 2007).  African tribes like the Zulu, Xhosa, and Sotho all have different traditional 
names for Artemisia afra.  Popular names include „wilde als‟ or „als‟ in Afrikaans, 
„mhlanyane‟ in Zulu, „umhlonyane‟ in Xhosa, „zengana‟ in Southern Sotho and „lengana‟ in 
Pedi and Tswana (van Wyk and Gericke, 2005, Mukinda, 2007). 
 
1.2  Botany  
Artemisia afra is classified under the Magnoliphyt division, Mognoliphyta class (Asteridae 
subclass) and the Asterales order (Mukinda, 2007).  The species is graphically represented in 
figure 1.1 below.  It is an aromatic medium sized clump-forming, multi-stemmed perennial 
herb, growing up to two meters in height. It has a ribbed stem, multiple branches and a short 
rhizome.  Silver-grey leaves are finely divided.  The characteristic colour is due to the 
presence of fine leaf hairs, growing up to 80 mm long and 40 mm wide.  The leaves are 
alternative and oval. Pale yellow or cream coloured tubular florets, with few outer female and 
inner bisexual florets, occur in an elongated racemose panicle during summer.  The capitula 
are all small, and the receptacle is flat and naked.  Fruits produced from the flowers are 1 mm 
in length, 3-angled and slightly curved with a silver-white coat.  The aerial parts have a 
characteristic „wormwood‟ smell and a bitter taste.  Artemisia afra is drought resistant, hardy, 
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and easy to propagate.  It grows well in any soil, needing only occasional watering and 
pruning (van Wyk and Gericke, 2005; Mukinda, 2007). 
 
Figure: 1.1:  Aerial parts  (traditional parts used) of Artemisia afra (van Wyk and Gericke, 2005:  45) 
 
1.3  Geographical distribution 
Artemisia afra grows naturally in Eastern and Southern Africa at altitudes ranging between 
1500 and 3000 m and in a wide variety of soils.  In South Africa, it normally grows in the 
mountainous areas along forest margins and streams.   The natural distribution extends from 
the Northern and Eastern Mpumalanga, Limpopo and the North West Province to the 
Western Cape.  It does not occur naturally in the Northern Cape.  It also occurs northwards 
into tropical east Africa as far north as Ethiopia (van Wyk and Gericke, 2005; Mukinda, 
2007).  This natural area of distribution can be seen in figure below in figure 1.2. 
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Figure 1.2:  Natural distribution of Artemisia afra in South Africa (van Wyk and Gericke, 2005:  44) 
 
1.4  Traditional medicinal uses of Artemisia afra 
Therapeutically Artemisia afra is used as an analgesic and anthelmintic.  Other traditional 
uses include a variety of ailments.  These include coughs, colds, sore throats, gumboils, 
influenza, asthma, whooping cough, bronchial complaints, diabetes mellitus, stomach 
ailments, measles, malaria, wounds, indigestion, heartburn, flatulence, colic, headache, 
earache, constipation, haemorrhoids and gout.  In the Cape region of South Africa it is 
popularly used as a bitter tonic and to help stimulate a poor appetite.  The plant is also said to 
be an anti-histaminic and is used to treat allergies.  The fresh or dried leaves and stems are 
used to make medicinal preparations in the form of teas, decoctions and tinctures.  The steam 
and fumes are inhaled to clear headaches, congestion, asthma, hay fever and sinusitis 
(Mukinda, 2007; van Wyk and Gericke, 2005; van Wyk, 2008).  The leaves may also be 
rolled and stuffed into the nostril to kill inhaled bacteria when visiting the ill.  Because of the 
great diversity of ailments treated with Artemisia afra, it is widely considered a “cure all” 
remedy (Mukinda, 2007).    
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The leaves and flowers are the main parts used in traditional medicine.  This is normally 
administered orally as a tea or a decoction.  Alcoholic extracts or tinctures are also a popular 
dosage form.  The roots may also be used medicinally, although this is not commonly 
practised (Mukinda, 2007; van Wyk and Gericke, 2005). 
 
1.5   Traditional dosage forms of Artemisia afra 
Artemisia afra is mostly taken as a tea or decoction.  It may also be taken as a „steam‟, where 
the vapours arising from the leaves in boiling water are inhaled.  Infusions or decoctions are 
made with variable quantities of fresh or dried leaves and is used to treat various ailments 
(Mukinda, 2007).   
The most common method of preparing a tea is to add a quarter cup of fresh leaves to one 
cup of boiling water, allow it to steep for five minutes, and strain before drinking.  One 
tablespoon of dried leaves could alternatively be added to one cup of boiling water, and 
allowed to steep for twenty minutes (Mukinda, 2007). 
A decoction can be prepared by pouring two litres of boiling water over one cup of fresh 
leaves and stems.  This is then allowed to stand for an hour before straining.  The filtrate can 
then be used as a wash for haemorrhoids and in a bath for measles, to treat fevers, as a 
wound-wash for sores, rashes, bites, stings, and as an eyebath diluted with warm water to 
soothe red, irritated eyes.  An enema may be made with ground leaves and hot water and 
given to children suffering from intestinal worms or constipation (Mukinda, 2007). 
A ‘strong brew’ that is used as a mouthwash for gumboils and oral ulcers, or as eardrops for 
earache can be made by adding one and a half or two cups of boiling water to a quarter cup of 
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Artemisia afra leaves.  The leaves are allowed to draw for ten minutes before it is strained 
and used (Mukinda, 2007). 
Another popular preparation is „Wilde als brandy,’ which is an old remedy for colds, coughs, 
chest ailments, indigestion and stomach cramps.  One bottle of brandy is mixed with one cup 
of Artemisia afra leaves, a quarter cup thyme, half a cup of mint leaves, one cup of sugar, one 
thumb-length piece of ginger and a quarter cup of rosemary.  All the ingredients are pushed 
into the brandy bottle and shaken every day for a month.  It is then either strained or allowed 
to age by adding more herbs.  One tablespoon is then mixed with water and taken as needed 
(Mukinda, 2007). 
For inhalation purposes, two or three cups of leaves are placed in a bowl with enough boiling 
water to cover. A towel is draped over the patient‟s head, with the bowl held under the nose.  
The steam is then deeply inhaled until the brew cools. This traditional method of 
administering Artemisia afra is used to treat bronchitis, a blocked nose or tight chest, asthma 
and chest colds (Mukinda, 2007). 
A wash can also be made for skin ailments, and warm leaves can be used as a poultice to 
draw out pimples and boils.  The poultice may also be used for neuralgia, mumps, painful and 
tired muscles, or bound over the abdomen to treat colic (Mukinda, 2007). 
Leaves may be rolled and inserted into the nostrils to alleviate headache and a blocked nose, 
or a fresh leaf may be packed in the gaps of the teeth to relieve toothache. The dried leaf may 
also be smoked to relieve a sore throat and tight chest, to expel phlegm and to treat coughs 
(Mukinda, 2007). 
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1.6  The chemical constituents of Artemisia afra  
Artemisia afra contains a high content of volatile oils, which varies depending on the 
geographical origin of the plant.  The volatile oils are responsible for the ant-microbial and 
anti-oxidant activity associated with the plant.  Often present are 1.8-cineole (eucalyptol), 
alpha-thujone, beta-thujone, camphor, borneol and sesquiterpenoids such as chrysanthenyl 
acetate and devannone.  Sesquiterpene lactones (guaianolides and glaucolides) have been 
isolated from the aerial parts, and are responsible for the digestive effects such as its anti-
spasmodic and appetite stimulating properties.  Non-volatile constituents include triterpenes 
(amyrin and friedelin), alkanes (ceryl cerotinate and N-nonacosane), and flavonoids (methyl 
ethers of luteolin), coumarins (scopoletin) and plyacetylens (Addea-Nensai, 1999; Mukinda, 
2007;  van Wyk and Gericke, 2005 and van Wyk, 2008). 
 
1.6.1  Non-volatile Constituents 
1.6.1.1  Flavonoids 
Flavonoids are phenolic compounds widely present in the plant kingdom.  They are 
responsible for the yellow colour of certain flowers and fruit.  Flavonoids occur either as free 
aglycones or bound to a sugar as a glycoside.   Flavonoid glycosides may be either an O- or  a 
C-glycosides, depending on the type of bond existing between the sugar and aglycone region 
(Evans, 2005). 
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Figure 1.3:  Flavonoid structure (Evans, 2005:  246) 
 
1.6.1.1.1  Classification of flavonoids 
All flavonoids are polyphenols consisting of a basic C6-C3-C6 skeleton.  They are yellow 
pigments occurring in the cell sap of higher plants and young tissue.  Depending on the 
variation of their basic carbon skeleton structure, flavonoids will be classified into a specific 
sub-group.  Classification can be done using one of four systems.  These systems include:  
classification according to the degree of saturation, the biosynthetic origin of the flavonoid, 
the molecular size of the flavonoid, and flavonoid conjugates.  Discrepancies exist regarding 
the classification of flavonoids, but the major sub-groups are normally considered as the 
flavonols, flavanones, flavones and the chalcone flavonoids (Evans, 2005).  Others may 
include isoflavonoids and anthrocyanadins.  Luteolin, most commonly found in the Asteracea 
family, is a flavonoid known as a flavone, (Mukinda, 2007). 
 
1.6.1.1.2  Biological effect of flavonoids 
Flavonoids display a wide range of biological activities.  These include anti-oxidation, anti-
inflammation, anti-platelet, anti-thrombotic, anti-allergenic, anti-carcinogenic, cardio-
protective, anti-proliferative, anti-microbial, anti-mutagenic, enzyme inhibitory, immune-
modulating and biological modifying actions (Bone and Mills, 1999).   
 
 
 
 
8 
 
Luteolin is a yellow crystalline compound found in Artemisia afra and in foods like parsley, 
artichokes, celery, peppers, olive oil, rosemary, citrus fruits, sage and thyme.  It normally 
occurs as luteolin-7-O-glucuronide, luteolin-5-O-glucuronide or luteolin-3‟-glucuronide.  It is 
reported to have platelet aggregation effects (Mukinda, 2007). 
 
Figure 1.4:  Luteolin (flavone) structure (Evans, 2005:  246) 
Luteolin is an anti-oxidant and vasodilator, anti-inflammatory, anti-allergenic, anti-
carcinogenic, immune-modulating and anti-spasmodic.  It also appears to be hypoglycaemic 
agent and to aid in weight management.  It also helps the body to better tolerate radiation and 
chemotherapy  (Mukinda, 2007). 
 
1.6.1.2 Scopoletin 
Socopoletin is a yellow-beige crystalline powder, also known as 7-hydroxy-6-
methylcoumarin, gelseminic acid, chrysatropic acid or esculetin-6-methyl ether.  It belongs to 
the group of coumarines, which are commonly used to treat clotting disorders such as 
thrombophlebitis, pulmonary embolism and certain cardiac conditions.  Scopoletin may act as 
both a hyper- and hypotensive agent (Kim, et al., 2004).  It is a nonspecific anti-spasmodic 
agent, due to its ability to inhibit the intracellular calcium mobilization from the 
noradrenaline-sensitive stores, helping to keep blood vessels dilated (Obidoa et al., 2005; 
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Oliveira et al., 2001).  However, it also appears to increase total serum cholesterol levels, free 
cholesterol levels and serum phospholipid levels, but decreases the levels of the serum 
esterified cholesterol (Oliveira et al., 2001).  In this way it appears to act as both a hyper- and 
hypotensive agent (Kim et al., 2004).    
The phytochemical webpage describes scopoletin as having bacteriostatic activity against 
Escherichia coli, Staphylococcus aureus, Streptococcus species, Klebsiella pneumoniae and 
Psuedomonas aeruginosa.  It is anti-inflammatory and can be used to treat bronchial illnesses 
and asthma.  It regulates serotonin levels/, helping to reduce anxiety and depression (Duke, 
2008).  Scopoletin suppresses pro-inflammatory cytokines and prostaglandin E2 (PGE2) 
(Kim et al., 2004).  
 
Figure 1.5:  Structure of scopoletin (Phytochemicals 2009) 
Scopoletin occurs in oats, horse chestnut, lavender, strawberries, cinnamon, and various 
Artemisia species (Artemisia annua, Artemisia capillaries, Artemisia afra and Artemisia 
dracunculus).  Biological activities associated with scopoletin include being anti-septic, 
diuretic, anti-asthmatic, anti-arrhythmic and anti-bronchoconstrictor.  It is also an analgesic 
by blocking inflammation through inhibiting inducible nitric oxide synthase (iNOS) (Obasi et 
al., 1994; Duke, 2008;  Monoforte, 1995).   
Scopoletin has a dual action on tumoural lymphocytes, exhibiting both a cytostatic and a 
cytotoxic effect, indicating that it could be a potential anti-tumour compound to be used for 
cancer treatment (Kang et al., 1999).  Scopoletin decreases the levels of serum thyroid 
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hormones and glucose.  It also decreases hepatic glucose-6-phosphatase activity, 
demonstrating a potential to regulate both hyperthyroidism and hyperglycemia. It inhibits 
hepatic lipid peroxidation and also increases the activity of antioxidants, superoxide 
dismutase and catalase (Manuele et al., 2006). 
 
1.6.1.3   Triterpene Constituents 
 
Figure 1.6:  α- and β-Amyrin (Evans, 2005:  298) 
Amyrin and friedelin are triterpene compounds present in Artemisia afra.  Amyrin is known 
to be anti-depressant and anxiolytic (Aragão et al., 2006).  It has also been found to inhibit 
inflammation, (Medeiros et al., 2007).   
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1.6.2  Volatile Compounds 
1.6.2.1  Volatile Oils 
Most volatile oils are mixtures of hydrocarbons and oxygenated compounds derived from 
these hydrocarbons.  These oxygenated compounds are responsible for the characteristic 
odour of many plants.    Most volatile oils are terpenoid, while some are aromatic (benzene) 
derivatives mixed with terpenes (Evans, 2005).   
 
Figure 1.7:  Eucalyptol (1,8-Cineole) (van Wyk and Gericke, 2005:  44) 
Eucalyptol is a volatile oil also known as 1.8 cineol.  It is mainly found in Eucalyptus species, 
but is also present in Artemisia afra.  It is a powerful anti-inflammatory and inhibits tumour 
necrosis factor-alpha (TNF-α) and interleukin 1beta (IL-1β).  It is thought to be useful in 
reducing the severity of asthma, sinusitis and chronic obstructive pulmonary disorders 
(COPD)  (Jeurgens et al., 2004).   It also helps prevent gastrointestinal inflammation and 
ulceration (Santos et al., 2004).  
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Figure 1.8:  Borneol (van Wyk and Gericke 2005: 44) 
Borneol is a bicyclic monoterpene volatile oil used for analgesia and anaesthesia in 
traditional Asian medicine.  It is found in many medicinal herbs, including Artemisia afra.  
Borneol has been found to have a positive modulating action at gamma aminobutyric acid 
(GABA) receptors (Granger et al., 2005). 
 
1.6.2.2  Sesquiterpene lactones 
Sesquiterpene lactones are a volatile oil subgroup, consisting of the most volatile plant 
constituents.  They are all formed from acetyl co-enzyme A (acytyl CoA) or glycolytic 
intermediates.  They consist of 15 carbon atoms with isoprene as the basic structural unit 
(Evans, 2005).  Sesquiterpene lactones are the main active ingredients in Chrysanthemum 
parthenium, commonly known as feverfew.  These lactones are responsible for inhibiting 
platelet aggregation and the formation of prostaglandins and leucotrines.   Sesquiterpene 
lactones are also anti-inflammatory, spasmolytic, anti-microbial and cytotoxic (van Wyk and 
Gericke, 2005).  Chrysanthenyl acetate is a sesquiterpene lactone found in Artemisia afra. 
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1.7  Pharmacology and toxicology 
Few studies have been conducted on indigenous herbs, including Artemisia afra.  Due to the 
harmful effects of thujone (possible addiction and cerebral dysfunction resulting from 
neurotoxicity), high doses and chronic use of Artemisia afra is discouraged.  Sporadic 
ingestion of small amounts of thujone in medicinal preparations and in food products does 
not, however, appear to be a health risk (van Wyk and Gericke, 2005). 
Aqueous extracts appear to be non-toxic when administered acutely, and there is a low 
chronic toxicity potential.  Hepatotoxic effects could result from high doses (Mukinda, 2007). 
 
1.8  Side effects of Artemisia afra 
In herbal medicine, Artemisia is considered as one of the great bitters.  All species of 
Artemisia should be avoided during pregnancy.  Thujone encourages menstruation and acts as 
an abortifacient.  It should not be given to children, epileptics and to patients suffering from 
duodenal ulceration.  According to herbal medicine lore, patients with a dry cough and severe 
kidney pathology should also avoid using Artemisia species (Kim et al., 2005).   
 
Figure  1.9:  α and β thujone (van Wyk and Gericke, 2005:  44) 
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Commonly known as absinthism, the effects of excessive or prolonged ingestion include 
restlessness, vomiting, vertigo, tremor, convulsions and fatty degeneration of the liver (van 
Wyk and Wink, 2004).  The effects of thujone are mediated by modulation of the gamma-
Aminobutyric acid (GABA)A receptors.  Inhibition of the serotonin 5-HT3 receptors is also 
thought to be involved, (Deiml et al, 2004).  Published data from clinical trials in humans is 
very limited in this field. 
 
1.9   Studies involving Artemisia 
Table 1.1 summarizes the various Artemisia species previously studied as well as their 
traditional uses.  Scientifically validated uses are briefly discussed in the section below. 
Table 1.1:  A brief overview of some Artemisia species studied 
Botanical Name Synonyms Geographical 
Source 
Traditional Uses Reference 
Artemisia afra Wilde als, African 
wormwood 
Southern and 
Eastern Africa 
Colds, flu, fevers, 
diabetes 
van Wyk and 
Gericke, 2004 
Artemisia annua Sweet wormwood, 
Qing Hao 
South East Europe, 
Western Asia 
Anti-malarial, 
fevers, colds, 
antibiotic 
van Wyk and 
Gericke, 2004 
Artemisia asiatica Asian wormwood Eastern Asia Inflammation, 
gastric ulcers 
Reddy et al., 
2006; Seo et 
al., 2001 
Artemisia 
capillaris 
Capillary 
Artemisia, Yin 
Chen Hao 
Eastern Asia Hepatitis, jaundice,  
biliary infection 
and fevers 
Jang, 2005 
Artemisia 
drcunculus 
Tarragon, Russian 
tarragon 
Russia, Western 
Asia, Himalyas. 
Intestinal worms, 
stomach cramps, 
sleep disorders, 
toothache 
Mars, 2007 
Artemisia 
iwayomogi 
Russian wormwood Eastern Asia:  
Afghanistan, India, 
Tibet, China & 
Traditional Korean 
medicine, anti-
inflammatory 
Kim et al., 
2005 
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Mongolia  
Artemisia 
princeps 
Artemisia indica Eastern China, 
Japan, Korea 
Digestive 
complaints 
Baek et al., 
2007 
Botanical Name Synonyms Geographical 
Source 
Traditional Uses Reference 
Artemisia 
verlotorum 
None Northern United 
States and Europe 
Hypertension Martinotti et 
al., 1999 
Artemisia vulgaris Mugwort  Mainly Britain and 
other northern 
temperate regions.   
Also found in Japan 
& Philippines   
Anti-septic, anti-
inflammatory, 
intestinal worms, 
insomnia 
Mars, 2007; 
Tingo et al., 
2000; van 
Wyk and 
Gericke, 2004 
 
1.9.1  Studies involving Artemisia afra 
1.9.1.1. Anti-microbial studies 
Focus has been mainly placed on Artemisia afra’s anti-microbial effects, especially that of 
the essential oils, although studies have been done using alcoholic and aqueous extractions.  
Artemisia afra has been found to be active against amoeba, Streptococcus pyogenes, Listeria 
monocytogenes and Acinetobacter johnsonil (Gundidza, 1993).  Methanol extracts have 
shown activity against Staphylococcus aureus, Staphylococcus epidermis and Bacillus 
subtilis.  No activity was found against Escherichia coli and Klebsiella pneumoniae (Rabe 
and van Staden, 1997).   
 
1.9.1.2  Cardiovascular studies 
The cardiovascular effects of aqueous extracts of Artemisia afra as well as a mixture of long 
chain fatty esters and scopoletin (isolated from Artemisia afra) were investigated by Addea-
Nensia and Guantai in 1999. The long chain fatty esters induced hypotensive effects. The 
 
 
 
 
16 
 
diastolic pressure was affected more than the systolic pressure. The aqueous extract had a 
hypotensive effect in vivo and a dose-dependent biphasic effect on the heart in vitro. Lower 
doses induced an initial cardio-stimulation followed by cardio-depression.  Higher doses were 
mainly cardio-depressant. Scopoletin induced a dose-dependent decrease in inotropic activity 
and decreased the chronotropic effects, suggesting that Artemisia afra is potentially useful in 
the management of hypertensive conditions.  
 
1.9.2  Biological studies involving other Artemisia species 
1.9.2.1  Anti-inflammatory studies  
Artemisia iwayomogi, commonly used as a traditional medicine in
 
Korea, has a known anti-
inflammatory effect.   One study found that
 
Artemisia iwayomogi inhibited plasma histamine 
release. It was also found to decrease Immunoglobulin (Ig) E–mediated local allergic 
reactions, as well as passive cutaneous
 
anaphylaxis reactions. A dose dependent decrease in 
histamine release from peritoneal mast cells activated by
 
IgE was also noted (Ahn et al;, 
2003; Kim et al., 2005 and Shin et al., 2006).  It also decreased calcium ionophore-stimulated 
tumour necrosis factor-alpha (TNF-α) and interleukin (IL)-6 gene expression and protein 
synthesis
 
in human mast cells. The inhibitory effect of Artemisia iwayomogi on the pro-
inflammatory
 
cytokines were found to be mitogen-activated protein kinases (MAPK) and
 
nuclear factor-kappa beta (NF-κβ) dependent (Ahn et al., 2003, Kim et al., 2005 and Shin et 
al., 2006).  Similar results were also found for Artemisia sylvatica (Jin et al., 2004). 
Artemisia capillaris is traditionally used in traditional Asian Medicine for the treatment of 
hepatitis and biliary tract infection.  It exhibited no cytotoxic effects in unstimulated 
macrophages, but reduced the release of nitric oxide (NO) and prostaglandin (PG) E2 when 
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stimulated by interferon-gamma/lipopolysaccharide (IFN-γ/LPS) or LPS. The inhibitory 
effects were found to be due to the suppression of inducible nitric oxide synthase (iNOS) and 
cylooxygenases-2 (COX-2) in IFN-γ/LPS stimulated cells.  It also decreased the production 
of TNF-α, interleukin (IL) -1β and IL-6 in LPS-stimulated cells, suggesting that it decreases 
the production of the inflammatory mediators (such as NO and PGE2) in macrophages by 
inhibiting iNOS and COX-2 expression (Jang et al., 2005). 
Artemisia asiatica is commonly used in oriental medicine to treat inflammation.  Ethanolic 
extracts of Artemisia asiatica inhibited histamine and leukotriene release in guinea pig lung 
mast cells activated with specific antigen/antibody complexes. Administered orally, it 
suppressed allergy-associated inflammation of the airways by regulating various cellular 
molecules expressed by the MAPK/NF-κβ pathway (Kim et al., 2006). 
Sesquiterpene lactones isolated from Artemisia leucodes also showed anti-inflammatory 
action in vivo (Schmidt et al., 2008).  Artemisia princeps reduced the IgE levels in the blood 
of asthmatic mice. It also reduced IL-6 and IL-4 levels in the trachea and lungs.  The 
transcription and translation of IL-6 and the TNF-α levels in cells that were Ig-E induced 
were also reduced (Beak et al., 2007). 
 
1.9.2.2 Anti-tumour studies 
Artemisia asiatica has been studied as a potential anti-cancer agent.  Ethanolic extracts inhibit 
tissue plasminogen activator (tPA)-induced COX-2 expression and iNOS (by blocking the 
NF-κβ signalling cascades) in a dose-dependant manner, indicating its use in depressing both 
inflammation and tumour promotion (Seo et al., 2001).   It has also been found to inhibit the 
NF-κβ transcriptional activity in LPS-stimulated macrophages (Reddy et al., 2006). 
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1.9.2.3  Cardiovascular studies  
Artemisia verlotorum, found in North America and Europe, is used as a folk medicine in 
some European countries as a hypertension remedy.  The dried aqueous extract has a 
significant but transient hypotensive effect in vitro. The hypotensive effect is mediated by a 
strong vasodilator action, and closely linked to the release of endothelial NO and to the cyclic 
guanosine monophosphate (cGMP) pathway, caused by muscarinic receptor agonims 
(Martinotti et al., 1999). 
A hydro-methanolic extract of Artemisia scoparia produced hypotensive and bradycardiac 
effects when administered intravenously. These effects were not mediated through the 
activation of the muscarinic receptors or adrenoreceptor blockade, because they remained 
constant in the presence of atropine, and did not modify the vascoconstrictor response of 
norepinephrine.  It also inhibited K
+
-induced tonic contraction in a manner similar to that of a 
calcium channel blocker such as verapamil (Gilani et al., 1994). 
Artemisia vulgaris is widely used in the Philippines for its anti-inflammatory properties.  It 
reverses the hypertensive action induced by norepinephrine. In another study, it did not 
significantly alter baseline blood pressures, but decreased the mean systolic and diastolic 
pressures induced by norepinephrine, without altering the heart rate in either normotensive or 
hypertensive states.  This study indicated that Artemisia vulgaris has an anti-hypertensive 
action but has no significant effects on cardiovascular hemodynamics under basal conditions 
(Tingo et al., 2000). 
Artemisia dracunculus is traditionally used in Iranian folk medicine as an anti-coagulant.  
Studies done with this species of Artemisia showed an inhibition in platelet adhesion. 
Methanol extracts also affected the self aggregation and protein secretion of the cells, 
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supporting its traditional use in the treatment of cardiovascular diseases and thrombosis 
(Shahriyary and Yazdanparast, 2008). 
 
1.9.2.4  Immunological studies 
The immunosuppressive activity and the inhibitory effect on the inflammatory and immune 
mediator, calmodulin, from artemisinin (extracted from Artemisia annua) was studied.  
Results showed an inhibitory effect on the activity of calmodulin. Both in vivo and in vitro 
studies indicated that artemisinin acted as an immunosuppressive agent (Noori, et al., 2004). 
 
1.9.2.5  Anti-diabetic studies 
Artemisia dracunculus, known for its antidiabetic activity, was examined as a possible aldose 
reductase inhibitor.  Aldose reductase is involved in carbohydrate metabolism, and is though 
to be responsible for diabetic complications involving a number of organs, such as the liver, 
eyes and nerves.  The enzyme activity was inhibited by 40 %, justifying its traditional use to 
help reduce diabetic complications (Logendra et al., 2006). 
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Chapter 2:  Artemsia afra and the immune system 
 
2.1  Introduction 
    
The immune system is comprised of Th1 and Th2 pathways.  If these pathways are 
imbalanced, inflammatory conditions such as asthma (initiated by a type I hypersensitivity 
reaction and sustained by a dominant Th2 pathway) and rheumatoid arthritis (resulting from a 
dominant Th1 pathway) may result.  A dominant Th1 pathway may also result from 
suppressing humoral pathways in conditions where the host is susceptible to bacterial, 
parasitic and extracellular infections.  Th2 pathway dominance suppresses cell-mediated 
immunity in conditions where the host is susceptible to viral invasion and other intracellular 
microbes such as Mycobacterium tuberculosis (Clark, 2009; Underwood, 2004).   
Artemisia afra is traditionally used to treat colds, influenza, asthma, allergies, rheumatic 
pains, tuberculosis (TB), and malaria (Mukinda, 2007; van Wyk and Gericke, 2005).  This 
suggests that it has a regulating effect on the immune system, potentially being able to 
address all aspects of immune dysfunction. 
 
2.2  Research problem 
In 2005, Rai described herbal forms of medicines becoming increasingly popular with the 
general public.  He also stated that medical practitioners were not well-equipped to guide the 
public on issues relating to herbal medicines as they have never seriously considered the idea 
that a herb could work as well as a pharmaceutical agent.  On their website, The World 
Health Organization (WHO) reports that in some African countries, up to 80 % of the 
population depend on traditional medicine for primary health care.   
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The WHO continues to describe some of the challenges facing traditional herbal medicines 
and those who use them.  The main one remains the lack of scientific data to critically 
evaluate the safety and efficacy of these medicines.  Many patients also believe that because 
herbal medicines are natural, they are safe and free of any side or adverse effects.  Adverse 
effects are common when the herb is taken incorrectly or together with other medications.  
This makes it necessary for increased training, collaboration and communication to exist 
between practitioners of herbal medicine and traditional Western medicine.  Methods of 
researching herbal products are complex, due to the hundreds of phytochemicals occurring in 
a single plant.  For every constituent to be properly evaluated, much time and resources 
would be required.  This is in turn closely related to the quality control involved in producing 
herbal medications, which is proving difficult to monitor.  Another key challenge is the lack 
of knowledge about herbal medicines within national drug authorities.  This leads to a delay 
in the creation of national policies, laws and regulations for traditional medicines.  In the July 
2008 edition of the Government Gazette, the South African minister of health, Dr 
Metshabalala-Msimang issued a draft policy concerning the incorporation of African herbal 
medicine into the health care system.   
In short, knowledge surrounding indigenous medicines is very limited, while the need for 
such knowledge is becoming more essential.  Most literature sources focus on the study of 
European herbs.  When indigenous herbs are researched, they tend to include 
pharmacokinetic studies involving HPLC, GC-MS and microbial assays.  These are often 
expensive, complicated and time consuming.  Another draw-back involving herbal research 
relates to the dosage and concentration of the herb used.  Most studies involve freeze-dried 
extracts or encapsulated samples, when most herbs are traditionally taken as an infusion (van 
Wyk and Gericke, 2005).  Long-term exposure of the herb also cannot be monitored using 
these procedures.   
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Biological studies also tend to be animal-related.  Although animal studies play a key role in 
understanding herbal pharmacology, interspecies differences regarding physiology may lead 
to the misunderstanding of certain herbal compounds, as they would not be metabolised the 
same way (Collins, 2001).  Most of these problems are eliminated when in vitro bioassays are 
employed, as they allow for quick and effective determination of the herb‟s effects on human 
physiology.  Rapid screens to asses the immune-modulating activity of indigenous herbs are 
required. Running these assays via whole blood cell cultures is preferred as only small 
amounts of blood are required and tests are done in vitro.  They can also be conducted 
quickly and represent the in vivo environment more accurately than isolated monocytes (Pool 
and Bouic, 2001).     
The following study aims to validate in vitro methods to monitor immune functions.  A whole 
blood culture assay will be used.  Inflammatory effects will be studied using IL-6, while 
immune function via Th1 and Th2 pathways will be monitored using IL-10 and IFN-γ 
cytokines.   
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Chapter 3:  Validation of whole blood cell assays to monitor immune 
function 
3.1  The immune system 
3.1.1  Introduction 
The immune system functions by protecting the body from invading pathogens that are 
potentially harmful.  Normal individuals have two levels of defence against these foreign 
agents.  The first level is referred to as natural or innate immunity.  It presents in neonatal 
animals and invertebrates.  The second type of immunity is adaptive or acquired immunity.  
Adaptive immunity is specific to vertebrates (Clark, 2009). 
Despite the distinct functions each of these immune components, interplay between these 
systems does exist.  Each system also consists of both cellular and humoral components 
(Mayor, 2000).   An overview of the immune system is graphically represented below in 
figure 3.1.  Comparisons between the innate and acquired immunity are briefly represented in 
table 3.1. 
 
Figure 3.1:  Immune system overview (Mayor, 2000) 
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Table 3.1:  Comparisons between innate and adaptive immunity (Mayor, 2000) 
Innate Immunity Adaptive Immunity 
Response is antigen independent Response is antigen dependent 
Immediate maximal response Lag time between exposure and maximal 
response 
Not antigen-specific Antigen specific 
No immunological memory Immunological memory 
 
 
3.1.2  Non-specific (innate) immunity 
 Innate immunity involves acute inflammation.  All components of the innate immune system 
are regulated by mediators of the adaptive immune system, such as interleukins, IFN-γ and 
antibodies (Mayor, 2000).   
 
3.1.2.1 Anatomical barriers of the innate immune system 
The innate immune system consists of anatomical barriers, cellular components and secretory 
molecules.  The anatomical barriers themselves can be divided into three groups of defences:  
mechanical defences, chemical defences and biological defences. Mechanical defences 
involve epithelial layers.  The skin serves as the initial defence.    Pathogens that adhere to 
epithelial surfaces are removed by desquamation.   In the lungs, cilia keeps air passages free 
from microbes, while in the gastrointestinal tract (GIT), peristalsis serves a similar function. 
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Tears and saliva help flush out the eyes and mouth.  Mucous linings in the GIT and 
respiratory tract provide additional protection (Mayor, 2000). 
Chemical defences consist of fatty acids in sweat that inhibits bacterial growth. Tears, saliva 
and nasal secretions contain lysozyme and phospholipase.  This damages bacterial walls and 
membranes. The low pH of sweat and gastric secretions prevents bacterial growth. Low 
molecular weight proteins called defensins occur in the lungs and GIT.  These exert 
antimicrobial activity.  Lung surfactants act as opsonins and promote phagocytosis (Mayor, 
2000).    
Biological factors include non-pathogenic flora occurring on the skin and in the GIT.  These 
prevent pathogenic colonization by secreting toxins or through competitive inhibition 
(Mayor, 2000).   
 
3.1.2.2  Humoral barriers of the innate immune system 
Acute inflammation results when mechanical barriers are ineffective.  Humoral factors then 
initiate oedema and an influx of phagocytes.  These humoral factors are found in the serum, 
while some are formed on demand at the infection site (Mayor, 2000).   
The complement system is the primary humoral mechanism of innate immunity.  It is 
responsible for increased vascular permeability, lysis and opsonisation of bacteria and the 
recruitment of phagocytes.  Tissue damage may activate the coagulation system.  This results 
in increased vascular permeability (Mayor, 2000).     
Bacterial cells require iron to grow.  They acquire this iron directly from the host iron-
binding glycoprotein, transferrin (Tf) (Moraes et al., 2009).  Lactoferrin, a humoral 
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component of the immune system produced by mucosal secretions, chelates iron molecules, 
preventing bacterial infection (Singh, et al., 2002).  Other humoral factors include interferons 
(IFNs), proteins produced by immune cells to limit viral replication in the host, and 
lysosomes which are released to destroy bacterial cell walls (Mayor, 2000).  
 
3.1.2.3  Cellular barriers of the innate immune system 
Macrophages and polymorphonuclear eosinophiles are vital to innate immune responses and  
inflammation.  Polymorphonuclear cells (PMNs), or neutrophils, are recruited to the infection 
site.  They phagocytose invading pathogens and kill them intracellularly. During 
inflammation, PMNs also cause collateral tissue damage.  Macrophages and monocytes 
(which differentiate into macrophages) act as additional phagocytes. Macrophages are 
capable of both intracellular and extracellular killing of infected cells.  Unlike PMNs, 
macrophages contribute to tissue repair and act as antigen-presenting cells (APCs).  These 
APCs induce specific immune responses (Mayor, 2000). 
 NK cells and lymphokine activated killer (LAK) cells non-specifically kill virus infected and 
tumour cells. They do not form part of the inflammatory response.  Eosinophils contain 
granular proteins responsible for eliminating various parasites (Mayor, 2000). 
 
3.1.2.4  Phagocytosis and intracellular immunity 
PMNs are motile phagocytic cells identified by their nucleus or the CD66 antigen present on 
their surface. Primary granules occur in newly formed PMNs.  These contain defensins to kill 
bacteria, lysozyme to break down bacterial cell walls and myeloperoxidase which produces 
bacteriocidal compounds.  Mature PMNs contain granules consisting of lysozyme, reduced 
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nicotinamide adenine dinucleotide phosphate (NADPH) oxidase components ( these generate 
toxic oxygen products) and lactoferrin (responsible for chelating iron).  Monocytes 
(macrophages) are phagocytic cells that have a kidney-shaped nucleus and can be identified 
by their CD14 cell surface marker. They contain numerous lysosomes that have contents 
similar to PMN granules (Mayor, 2000).   
Once the PMNs are recruited, ingestion (phagocytosis) and intracellular killing of the 
pathogen and clearing of cellular debris occurs. Phagocytosis occurs by pseudopodia 
formation (cytoplasmic membrane projections) around the pathogen.  The podia eventually 
fuse to form a membrane-bound vesicle (phagosome).  This then fuses with the neutrophil 
cytoplasmic granules (phago-lysosome).  It is within this localized environment that the 
pathogen is killed, while the remaining cytoplasm remains protected (Kumar and Clark, 
1999). 
In this phago-lysome, killing occurs via one of two methods.  An oxygen-dependant response 
or “respiratory burst” results in the production of reactive oxygen metabolites, by reducing an 
NADPH oxidase present in the phagocyte cytoplasm.  An oxygen-independent response 
results due to the toxic action of preformed cationic proteins and enzymes found in the 
neutrophil cytoplasmic granules (Kumar and Clark, 1999). 
 
3.1.2.5  Complement 
The term complement (C) was traditionally used to refer to a heat-sensitive serum compound 
capable of lysing bacteria, but compliment is also responsible for other types of defences.  
These include eradicating immune complexes and pathogenic organisms and 
immunoregulation. Effects detrimental to the host may also result from complement as it 
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induces inflammation, tissue damage and may trigger anaphylaxis (Kumar and Clark, 1999; 
Mayor, 2000).  
Complement consists of more than 20 serum proteins.  These are produced by hepatocytes, 
macrophages and GIT epithelial cells. When cleaved, certain complement proteins produce 
fragments that activate cells, increase vascular permeability or opsonize bacteria (Mayor, 
2000).  Complement can be activated by one of four pathways.  Primary pathways are 
represented in figure 3.2 below. 
 
3.1.2.5.1  The classical pathway 
The classical pathway consists of four stages.  In the first stage, C1, a multi-protein 
containing various proteins (C1q, C1r and C1s), binds to the Fc region of an IgG and IgM 
antibody (that have interacted with an antigen).  This binding of C1 to the antibody occurs via 
C1q and C1q and must cross link at least two IgG antibody molecules before it is firmly 
fixed.  The binding of C1q results in the activation of C1r which in turn activates C1s.  The 
result is the formation of an activated “C1qrs”, an enzyme that cleaves C4 into two 
fragments;  C4a and C4b (Kumar and Clark, 1999; Mayor, 2000).   
C4b (promotes phagocytosis) binds to the pathogen membrane while C4a is released.  
Activated “C1qrs” also cleaves C2 into C2a and C2b.  C2a binds to the membrane in relation 
with C4b.  C2b is released (results in oedema).  This forms a C4bC2a complex, which is a C3 
convertase.  C3 convertase cleaves C3 into C3a and C3b (Mayor, 2000).  
C3b (activates phagocytosis) binds to the membrane in relation with C4b and C2a, while C3a 
is released (may result in anaphylaxis).  This results in a C4bC2aC3b molecule, which is a C5 
convertase.   C5 convertase production marks the end of the classical pathway.  Various 
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regulators control the activity of the classical pathway (Kumar and Clark, 1999; Mayor, 
2000).  
 
3.1.2.5.2  The lectin pathway 
     The lectin pathway is similar to the classical pathway.  It is initiated by mannose-binding 
lectin (MBL).  MBL is a circulating protein that binds to carbohydrate molecules on the 
surface of certain microbes.  As MBL is structurally related to C1q, it activates complement 
through MBL-associated serine proteinase (MASP), which is similar to C1r and C1s of the 
classical pathway.  The biological activities and regulatory proteins of the lectin pathway are 
similar to that of the classical pathway.  This pathway also contributes to the regulation of the 
innate immune system (Kumar and Clark, 1999). 
 
      3.1.2.5.3  The alternative pathway 
The alternative pathway is considered to be the more primitive pathway, while the classical 
and lectin pathways are thought to have developed from it.  It begins with an activated C3 
and requires Factor B, Factor D and Mg
++
 cations, (all of which occur in healthy serum).  
Serum normally has low levels of spontaneous hydrolysis of C3 to produce C3i. Factor B 
binds to C3i and becomes susceptible to Factor D.  This cleaves Factor B into Bb. The C3iBb 
complex serves as a C3 convertase.  It cleaves C3 into C3a and C3b. When C3b is formed, it 
binds to Factor B and becomes susceptible to cleaving by Factor D. The resulting C3bBb 
complex is a C3 convertase.   This will generate more C3b, amplifying C3b production  
(Mayor, 2000).    
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      When bound to an appropriate activator, C3b binds Factor B, which is cleaved by Factor D to 
produce C3 convertase (C3bBb).  C3b is resistant to Factor I degredation.  C3 convertase is 
degraded slowly, as it is stabilized by the activator surface.  The complex is further stabilized 
by properdin binding to C3bBb.  Surface components of various pathogens act as activators 
in this pathway.  They include lipopolysaccharide (LPS) from Gram-negative bacteria and the 
cell walls of certain yeasts and bacteria.  When C3b binds to an activator, the C3 convertase 
formed is stable and continues to generate additional C3a and C3b by cleavage of C3 (Mayor, 
2000). 
     Some of the C3b generated by stabilized C3 convertase associates with the C3bBb complex. 
This forms a C3bBbC3b complex - the C5 convertase of the alternative pathway.  The 
production of C5 convertase marks the end of this pathway.  It may be activated by numerous 
Gram-negative bacteria (Neisseria meningitidis and Neisseria gonorrhoea), some Gram-
positive bacteria, aggregated immunoglobulins (especially IgA) and certain viruses and 
parasites.  This results in the lysis of these pathogens. The alternative pathway functions as an 
additional defence mechanism against pathogens before an antibody response is initiated.  A 
deficiency of C3 results in an increased susceptibility to microbes (Mayor, 2000).   
 
3.1.2.5.4  The membrane attack (lytic) pathway 
      C5 convertase can be produced from either the classical (C4b2a3b), lectin (C4b2a3b) or 
alternative (C3bBb3b) pathways, to cleave C5 into C5a and C5b. C5a remains in the serum.  
C5b associates with C6 and C7 and inserts into the pathogen membrane. As a result, C8 
binds, followed by several molecules of C9. The C9 molecules form a pore in the membrane.   
Cellular contents leak through the pore.  Membrane damage results in lysis.  The complex 
 
 
 
 
37 
 
consisting of C5bC6C7C8C9 is referred to as the membrane attack complex (MAC) (Mayor, 
2000). 
      C5a generated in this pathway has numerous biological activities. C5a is the most powerful 
anaphylotoxin.  It is a chemotactic factor for neutrophils and initiates the respiratory burst in 
these cells.  Inflammatory cytokine production by macrophages is also stimulated (Mayor, 
2000;  Underwood, 2004).   
 
      Figure 3.2:  Compliment activation via the lectin, classical and alternate pathways (Underwood,   
2004: 175) 
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3.1.3  Immune cells  
Immune cells all originate in the bone marrow.  These cells include lymphoid cells and 
myeloid cells.  Each of these progenitor groups differentiate to form distinct cell types 
(Underwood, 2004).   
Myeloid progenitor stem cells in the bone marrow differentiate into erythrocytes, platelets, 
neutrophils, monocytes (macrophages) and dendritic cells.   Stem cells from the lymphoid 
progenitor differentiate into natural killer (NK) cells, thymus (T) cells and bone marrow (B) 
cells. For T cells to develop, the precursor T cells migrates to the thymus, where they 
differentiate into two distinct types of T cells;  the CD4+ Th cells and the CD8+ pre-
cytotoxic T cells.  In the thymus, two types of T helper cells are produced.  The first is the 
Th1 cells which help CD8+ pre-cytotoxic cells differentiate into cytotoxic T cells.  The 
second group of cells are the Th2 cells.  These help B cells differentiate into plasma cells, 
which secrete antibodies (Mayor, 2000).  Figure 3.3 below represents the various immune 
cells and how they develop within the body.  
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Figure3.3:  T and B cell development (Underwood, 2004: 170) 
 
3.1.3.1 Cells of the innate immune system 
These include phagocytic cells (monocyte/macrophages and PMNs), NK cells, basophils, 
mast cells, eosinophiles and platelets.  They have pattern recognition receptors (PRRs) that 
recognize broad molecular patterns found on pathogens (pathogen associated molecular 
patterns, PAMPS).  Antigen presenting cells (APCs) are heterogenous leukocytes vital in 
innate immunity.  They include macrophages and dentritic cells.  They link the innate 
immune system to the adaptive immune system by participating in the activation of helper T 
cells.  APCs all express class II MHC molecules.   Although B lymphocytes also express 
class II MHC molecules and also function as APCs, they are not considered part of the innate 
immune system.  In addition, certain other cells (thymic epithelial cells) can express class II 
MHC molecules and can function as APCs (Mayor, 2000). 
 
3.1.3.2  Cells of the acquired immune system 
B and T lymphocytes make up the acquired immune system.  After antigen exposure, B cells 
differentiate into plasma cells.  Their main function is now antibody production.  T cells 
differentiate into either T cytotoxic (Tc) or T helper (Th) cells of which there are two types,  
Th1 and Th2 cells (Mayor, 2000).  
 
3.1.3.3  Non-specific immune cells 
Large granular lymphocytes (LGL) or NK cells are identified by the CD56 and CD16  on the 
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cell surface.  They are responsible for targeting virus-infected cells. When exposed to IL-2 
and IFN-γ, NK cells become lymphokine-activated killer (LAK) cells which effectively 
eliminate malignant cells.  NK and LAK cells contain both a killer activating receptor (KAR) 
and a killer inhibiting receptor (KIR). When the KAR encounters its ligand, a killer activating 
ligand (KAL), the NK or LAK cell eliminates the pathogen.  When the KIR also binds to its 
ligand then killing is inhibited even if KAR is bound to a KAL. Ligands for KIR are termed 
MHC-class I molecules. Healthy cells express MHC class I molecules on their surface, while 
malignant and virus infected cells down regulate this expression, resulting in the selective 
elimination of cells (Mayor, 2000). 
Killer (K) cells are any cells that mediate antibody-dependent cellular cytotoxicity (ADCC). 
In ADCC, antibody acts as a link between the K cell (containing an Fc recptor) and the 
pathogenic cell. Killer cells include NK, LAK and macrophages (have an Fc receptor for IgG 
antibodies) and eosinophils (have an Fc receptor for IgE antibodies) (Mayor, 2000). 
 
3.1.4 Cytokines and immune regulation 
3.1.4.1  Cytokines 
Cytokines are a diverse group of non-antibody proteins that act as mediators between cells.  
Originally thought to be products of immune cells to mediate and regulate immune activity, 
they are also produced by cells other than those found in the immune system.  They may also 
have non-immune related functions.  Three main types of cytokines exist:  monokines, which 
are produced by mononuclear phagocytic cells;  lymphokines, produced by activated 
lymphocytes (mainly Th cells) and interleukins that act as mediators between leukocytes, 
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(Mayor 2000).  Figure 3.4 indicates the various cytokines and the cells they are released 
from. 
Cytokines produce cascades that up or down regulate the production of other cytokines.  
They influence the action of other cytokines by acting either additively, antagonistically or 
synergistically.  Cellular responses to cytokines normally take a few hours as they require 
new mRNA and protein synthesis (Mayor, 2000). 
 
Figure 3.4  Various cytokines secreted by Th1 and Th2 cells (Underwood, 2004:  174) 
IL-10 is produced by activated macrophages and Th2 cells. It functions mainly as an 
inhibitory cytokine in the acquired immune system.  It inhibits the production of IFN-γ by 
Th1 cells.  This shifts immune responses toward a Th2 pathway. It also inhibits cytokine 
production by activated macrophages.  This results in a down regulation of the immune 
response, inhibiting APC activity and cytokine production.  IFN-γ may also be produced by 
Tc and NK cells.  It has numerous functions in both the innate and adaptive immune systems.  
The anti-proliferation activity of IFN-γ is weaker than that of INF-α and IFN-β, but it is most 
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effective at activating macrophages and inducing class I and II MHC expression (Mayor, 
2000).  Additional immune-regulating functions of IFN-γ are represented in figure 3.5 below. 
 
Figure3.5:  Immunoregulatory effects of IFN-γ (Mayor, 2000)   
 
3.1.4.2  Immune regulation 
Immune activity is regulated by the balance between the antigen-driven activation of 
lymphocytes and the negative regulatory influences that prevent or down regulate the 
immune response.  Immune responses can also be regulated by antibodies.  This happens 
either by antibodies competing with antigen receptors on B cells, preventing B cell activation, 
or by the antigen-antibody complex binding to the Fc receptor of the B cell, sending an 
inhibitory signal to the B cells.   Regulatory T cells (Tregs) inhibit a sustained Th1 and Th2 
cell response and prevent chronic (potentially damaging) responses. They do not prevent 
initial T cell activation, (Mayor, 2000).  By avoiding a chronic inflammatory response and by 
maintaining Th1 and Th2 balance, both innate and adaptive immune systems remain 
balanced.   
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3.1.4.3  Th1/Th2 balance  
After recognizing a specific antigen presented by an APC, Th cells initiate several processes 
vital to the immune response.  These include the selection of appropriate effector mechanisms 
(B cell activation or Tc generation), inducing the proliferation of appropriate effector cells 
and enhancing the activities of other cells (macrophages and NK cells) (Mayor, 2000). 
When naïve Th0 cells encounter antigen in secondary lymphoid tissues, they may 
differentiate into either inflammatory Th1 cells or a helper Th2 cells (each of which produce 
different cytokines).  This differentiation depends on the surrounding cytokines, which is in 
turn influenced by the invading pathogen.  Some antigens therefore stimulate IL-10 
production (resulting in the production of Th2 cells) while other antigens stimulate IFN-γ 
production (which results in the production of Th1 cells).  These Th1 and Th2 cells affect 
numerous other cells and influence the type of immune response.  Cytokines that are 
produced by Th1 cells activate macrophages and Tc cell production, causing a cell-mediated 
immune response.  Cytokines that are produced by Th2 cells activate B cells, resulting in 
antibody production (humoral immune responses).  Th2 cytokines also activate granulocytes.  
Each pathway also inhibits the initiation of the other pathway.  IFN-γ, for example, produced 
by Th1 cells inhibits the proliferation of Th2 cells while IL-10 produced by Th2 cells inhibits 
production of IFN-γ by Th1 cells.  The immune response is therefore always directed to the 
type of response that is needed to deal with the specific pathogen encountered.  Cell-mediated 
responses are induced in cases of intracellular pathogens while antibody responses result due 
to extracellular pathogens (Mayor, 2000). 
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3.1.5 Adaptive (acquired) immunity 
Acquired immunity is recognized by three key features:  the ability to discriminate between 
self and non-self molecules, the ability to memorize and recognize specific antigens and this 
recognition results in a very specific immune reaction (Mayor, 2000).   
Adaptive immunity allows for the immune system to acquire a memory towards a specific 
pathogen.  The initial encounter with an antigen results in the primary immune response.  A 
repeated encounter with the same antigen results in the secondary response.  Secondary 
responses occur more rapidly and more efficiently due to the presence of pre-formed antigen 
specific lymphocytes (Clark, 2009).  This process is represented in figure 3.6. 
Antigen specificity occurs when the lymphocyte surface receptor recognizes specific parts of 
the antigen (antigenic epitopes). The cell surface receptor of B lymphocytes is an 
immunoglobulin molecule.  When this immunoglobulin is secreted by the B cell, it is known 
as an antibody (Clark, 2009). 
 
Figure 3.6:  Primary and secondary immune responses (Underwood, 2004:  174) 
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3.1.5.1  Antibody molecules (immunoglobulins) 
The basic structure of an antibody is made up of glycoproteins consisting of 2 heavy chains 
and 2 light chains.  This leads to the formation of a molecule that has two “arms” with 
antigen-binding sites, and a single stem that has the Fc portion which is not antigen specific 
and attaches to cellular immunoglobulin receptors. 
 
 3.1.5.2  Extracellular recognition 
Antibodies are the primary defense against extracellular pathogens and result in immune 
responses through one of three mechanisms.   
Neutralisation occurs by binding to the pathogen.  The antibody blocks the link between the 
pathogen and their targets.  Antibodies to bacterial toxins can prevent toxins from binding to 
the host cell by rendering the toxin ineffective (Clark, 2009; Mayor, 2000).   
Opsonisation allows for specific receptors on various cells, including macrophages, 
neutrophils, basophils and mast cells to recognize and respond to a certain antigen.  The Fc 
region of the antibody interacts with Fc receptors of the phagocytes, enhancing phagocytosis 
(Clark, 2009; Mayor, 2000). 
Antibody binding to pathogens can also activate the complement system.  Activation of 
complement results in pathogen lysis and enhances phagocytosis (Clark, 2009;  Mayor, 
2000).   
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3.1.6  In vitro and in vivo methods to monitor immune function 
 
To thoroughly investigate the immune system, both in vitro and in vivo experimentation is 
required.  In vitro investigation plays an important role in evaluating the release of various 
immune products which may increase antimicrobial potential.  However, presumption based 
solely on in vitro findings may lead to incorrect beliefs regarding immune function as they 
lack the complexity of specific microenvironments and homeostatic controls found in 
humans.  Such in vitro models may also be limited due to the use of the use of non-
physiological target cells.  After completing the in vitro model, it is largely required that the 
experiment be repeated in an animal model, to ensure that results have in vivo relevance and 
are not merely a by-product of the isolation process or the in vitro environment as these are 
overly simplistic (Silliman and Wang, 2006). 
Due to ethical and moral concerns regarding animal testing, many immune assays are done in 
vitro.  Animal models are useful in vivo to represent the human physiology. Due to the 
complexity of the immune system, especially with regards to issues relating to the discovery 
of different lymphocytes, proper distinction between T and B cells can only be properly 
recognized using animal models with intact immune systems with selective gene knockouts 
and chimeras.  Reconstituting lymphocyte development and immune responses in vitro has 
proven to be problematic.  Meaningful studies, particularly relating to the adaptive immune 
system, cannot be properly conducted outside an intact animal.  This fact has lead to the 
development of many genetically modified animals to improve understanding of the basic 
mechanism of adaptive immune activity.  Moreover, the role of complement in host 
protection can not be completed without using gene-targeting technology in mice (Silliman 
and Wang, 2006).   
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In vivo models also have their drawbacks.  One such limitation is that animal models do not 
accurately represent various human states, especially human pathology.  This increases the 
need for in vitro data to better correlate with in vivo function (Silliman and Wang, 2006).   
To fully understand human immunity, animal models are essential, as well as germ-line 
mutations and gene-targeting technologies.   In vitro models are however useful as screening 
profiles, to assess the selectivity of certain herbs and drugs, and determine certain immune-
side effects of various compounds.  In vivo models, on the other hand, are more specific to 
asses the therapeutic efficacy of these various drugs and herbal compounds and to help 
discover previously unknown disease indications for these compounds (Calipher Life 
Sciences, 2008).   
As far as we are aware, this is the first study of its kind used to examine Artemisia afra. In 
vitro methods were employed as they offer a quick and effective method to determine 
immunological effects.  Running in vitro assays via whole blood cell cultures was preferred 
as they represent the in vivo environment more accurately than isolated monocytes in terms of 
the immune system (Pool and Bouic, 2001).     
The following study aims to validate in vitro methods to monitor immune functions.  A whole 
blood culture assay will be used.  Inflammatory effects will be studied using IL-6, while 
immune function via Th1 and Th2 pathways will be monitored using IL-10 and IFN-γ 
cytokines.   
 
3.2  Methods 
3.2.1 Inflammatory activity 
Blood samples were collected from healthy male donors by venous puncture into citrate-
containing sterile blood collecting tubes (after informed consent).  Whole blood cultures were 
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conducted within 4 hours after collection.  All methods were performed under sterile 
conditions.  Stimulated whole blood cultures contained 1 volume of 10 µg/ml endotoxin in 
dimethyl sulfoxide (DMSO), 10 volumes of blood and 89 volumes of RPMI-1640 medium.  
Unstimulated blood contained 1 volume DMSO, 10 volumes of blood and 89 volumes of 
RPMI-1640.  The blood (stimulated or unstimulated;  200 µl/well) was incubated at 37 ˚C for 
24 hours.  Culture supernatants were then collected and assayed for LDH and IL-6.   
 
 
3.2.2  Th1/Th2 activity 
Stimulated whole blood cultures contained 10 volumes of blood, 89 volumes of RPMI-1640 
medium and 1 volume of 1.6 µg/ml phytohaemagglutinin (PHA) in RPMI.  The final 
concentration of PHA in the stimulated blood mixture was 1.6 µg/ml.  For unstimulated 
whole blood cultures, no additions were made to the diluted blood.  Stimulated or 
unstimulated blood (200 µl/well) cultures were incubated for 48 hours.  Culture supernatants 
were then used for IL-10 and IFN-g assays. 
 
3.2.3  Cytotoxicity assay  
A commercially available chromogenic lactate dehydrogenase (LDH) assay kit (Biovision, 
USA) was used to determine the cytotoxicity of samples.  Cell culture supernatants were 
collected from blood samples incubated for inflammatory activity.  Samples were transferred 
to a 96-well plate.  For the 100 % toxicity standard a control blood sample (250 µl) received 
2.5 µl of a 10 % volume/volume Triton X 100 solution.  The blood immediately lysed.  This 
lysed sample was mixed and an aliquot of the lysed blood was diluted in saline at a ratio of 
1:10.  The lysed blood sample was used as the 100 % cytotoxicity control.  Dilutions of this 
sample were used to construct a standard curve.  The standards were also transferred to the 
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96-well plate.  LDH substrate was added to samples.  Well contents were mixed (by tapping 
the plate).  Absorbance readings were taken at 10 minute intervals at 592 nm.  Between 
readings the plate was incubated away from light at ambient temperature.  The cytotoxicity of 
the samples were read off a standard curve constructed using the standards.   
 
3.2.4  Cytokine analysis 
Cytokine concentrations were determined using ELISA‟s .  ELISA kits were purchased from 
e-Bioscience, Denmark.  Kits contained all the reagents required for the assays.  The plates 
were coated with capturing antibody (50 µl/well) diluted appropriately with coating buffer.  
This was incubated overnight at 4 ˚C.  The plates were washed 5 times with wash buffer 
consisting of autoclaved PBS containing 0.05 % Tween-20.  Non-specific binding sites were 
blocked using assay diluent (100 µl/well) for 1 hour at room temperature.  Plates were again 
washed as before.    Cell free supernatants (50 µl/well) were added to the each plate.  The 
assay was standardized using a 2-fold serial dilution of a cytokine standard on each plate.    
The plates were sealed and incubated for 2 hours at room temperature.  The plates where then 
washed as before after which detection antibody (50 µl/well) was added.  The plates were 
incubated for 1 hour at room temperature.  After washing the plates five times, avidin-
horseradish peroxidise (HPR) was added (50 µl/well) to detect bound cytokines.  Plates were 
incubated for 30 minutes at room temperature and then washed 7 times with wash buffer.  
Substrate solution was added (50 µl/well) and incubated for 15 minutes in a dark area.  The 
reaction was stopped by adding 50 µl/well stop solution.  Absorbances were read on a plate 
reader at 450 nm. 
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3.3  Results and discussion 
3.3.1  Cytotoxicity 
Total LDH in the blood culture was obtained by lysing diluted whole blood with Triton X100 
% detergent.  The total LDH from the blood cultures was considered to be 100 % toxicity 
(after being released into the medium).  A standard curve was constructed from dilutions of 
the 100 % toxicity sample.  This curve (Figure 3.7) indicates good correlation between the 
absorbance values and the % toxicity (R
2
=0.983). 
 
Figure 3.7:  Standard curve of toxicity.   
 
3.3.2  Inflammatory activity 
Culture supernatants from LPS stimulated cultures were analysed for inflammatory activity 
using IL-6 as a biomarker.  Figure 3.8 is a representative example of a standard curve 
obtained using the IL-6 ELISA kit.  It shows that there is good correlation between the 
absorbance values and the cytokine concentration (R
2
=0.993). 
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Figure 3.8:  Standard curve for IL-6.  The kit standards were assayed by DAS ELISA according to 
the manufacturer‟s instructions. 
The IL-6 by stimulated whole blood cultures was 3418.3±4588.1 pg/ml while the absorbance 
for unstimulated blood was 31.9±35.9 pg/ml (n=9±SD). The data shows that there is statically 
significant difference between IL-6 secretions of the stimulated and unstimulated whole 
blood cell cultures (P<0.042) showing that this biomarker assay can be used to monitor 
inflammatory activity.    
 
3.3.3  Humoral immunity 
Culture supernatants from PHA stimulated cultures were analysed for humoral immune 
activity using IL-10 as a biomarker.  Figure 3.9 is a representative example of a standard 
curve obtained using the IL-10 ELISA kit.  It shows that there is good correlation between 
the absorbance values and the cytokine concentration (R
2
=0.999). 
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Figure 3.9:  Standard curve for IL-10.  The kit standards were assayed using the DAS ELISA 
according to manufacturer‟s instructions. 
The IL-10 released by stimulated whole blood cultures was 102.1±3.5 pg/ml while the 
absorbance for unstimulated blood was 2.0±4.9 pg/ml (n=9±SD). The data shows that there is 
statically significant difference between IL-10 secretions of the stimulated and unstimulated 
whole blood cell cultures (P<0.001) showing that this biomarker assay can be used to monitor 
inflammatory activity.    
 
3.3.4  Cellular immunity 
Culture supernatants from PHA stimulated cultures were analysed for cellular immune 
activity using IFN-γ as a biomarker.  Figure 3.10 is a representative example of a standard 
curve obtained using the IFN-γ ELISA kit.  It shows that there is good correlation between 
the absorbance values and the cytokine concentration (R
2
=0.999). 
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Figure 3.10:  Standard curve obtained for IFN-γ.  The kit standards were assayed by the DAS 
ELISA according to the manufacturer‟s instructions. 
The IFN-γ released by stimulated whole blood cultures was 3540.5±2126.8 pg/ml while the 
absorbance for unstimulated blood was 23.2±15.4 pg/ml (n=9±SD).  The data shows that 
there is statically significant difference between IFN-γ secretions of the stimulated and 
unstimulated whole blood cell cultures (P<0.001) showing that this biomarker assay can be 
used to monitor inflammatory activity.    
 
3.4.  Conclusion 
These results show that mitogen activated whole blood cultures can be used as an effective 
method to monitor immune function.  This study confirms earlier work that shows that 
cytokines are a sensitive indicator of immune modulation (Pool and Magcwebeba, 2008). 
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Chapter 4:  The immune-modulating activity of Artemisia afra, one of the 
indigenous herbs of South Africa 
4.1  Introduction 
Artemisia afra (Asteraceae) is one of the oldest and best-known of South Africa‟s indigenous 
medicines. The plant is also found in parts of Eastern Africa and is used as a medicine in 
Ethiopia (van Wyk and Gericke, 2005).  Wormwood, its common name, is derived from the 
Old English word „wermode‟, meaning “mind preserver” (Mars, 2007).  African tribes like 
the Zulu, Xhosa, and Sotho all have different traditional names for Artemisia afra.  One of 
these popular names include „wilde als‟ or „als‟ in Afrikaans, translating as „all‟ or 
„everything‟ as the herb is a common folk remedy for nearly every ailment (Mukinda, 2007).   
Therapeutically Artemisia afra is used as an analgesic and anthelmintic.  Because of the great 
diversity of ailments treated with Artemisia afra, it is widely considered a “cure all” remedy 
in South Africa and its neighbouring countries (Mukinda, 2007; van Wyk and Gericke, 2005; 
van Wyk and Wink, 2004). 
Artemisia afra contains various phenolic compounds such as borneol and other volatile oils 
that have anti-bacterial and anti-fungal action (van Wyk and Wink, 2004).  This helps to 
explain its popularity to help treat bacterial infections.  Bacterial infections traditionally 
treated with Artemisia afra include gumboils, sore throats, ear infections, whooping cough 
and certain bronchial complaints (Mukinda, 2007; van Wyk and Gericke, 2005).  The  
scopoletin (coumarin) compound found in Artemisia afra has been attributed with anti-viral, 
hypotensive and hypocholesterolaemic effects, (Manuele et al., (2006).  The presence of 
scopoletin helps justify traditional uses relating to viral conditions such as measles, mumps, 
colds and influenza.  
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In 2004 van Wyk and Wink reported that Artemisia afra has antihistamine activity.  This 
potentially explains its traditional use in the treatment of asthma and other allergies.  A 
possible mechanism of action in this regard is by down regulating the Th2 pathway.  Should 
Artemisia afra be capable of doing so by up regulating cell-mediated immunity, viruses and 
infections such as tuberculosis (TB) could be potentially treated using this herb.    Parasites 
(popularly treated using Artemisia afra) such as intestinal worms and malaria, are addressed 
via the humoral immune system.  Literature therefore suggests that Artemisia afra should 
have immune modulating activity; being able to suppress and activate both Th1 and Th2 
pathways, depending on the stimulus encountered by the host, rather than acting on only one 
of the pathways.   
Few studies have been conducted on indigenous herbs, including Artemisia afra.  Due to the 
harmful effects of thujone (possible addiction and cerebral dysfunction resulting from 
neurotoxicity), high doses and chronic use of Artemisia afra are discouraged.  Sporadic 
ingestion of small amounts of thujone in medicinal preparations and in food products does 
not appear to be a health risk (van Wyk and Gericke, 2005).  Aqueous extracts appear to be 
non-toxic when administered acutely and there is a low chronic toxicity potential.  
Hepatotoxic effects could result from high doses (Mukinda, 2007).   
The aim of this study is to investigate if Artemisia afra has immunomodulating activity in 
vitro, using whole blood culture assays as described in the previous chapter.   
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4.2  Materials and Methods 
4.2.1  Plant Extraction 
Artemisia afra samples were obtained and prepared for analysis. A 20 % (w/v) extract was 
prepared using 94.4 % ethanol by Parceval (Pty) Ltd pharmaceuticals (South Africa).  Aerial 
parts of the plant were milled (sieve size~ 2 - 3 mm) and mixed with 94.4 % ethanol at 20 g 
Artemisia afra per 100 ml ethanol.  The mixture was shaken for brief periods during 
overnight extraction. The extracts were then pressed to separate the resulting tincture from 
the milled leaves. The tincture was filtered and the extracts were stored at 20 ˚C.  The extract 
was air dried and re-suspended in DMSO to obtain a 50 % (wet leaf w/v) extract.  
 
4.2.2 Anti-inflammatory activity 
Blood samples were collected from healthy male donors by venous puncture into citrate-
containing sterile blood collecting tubes (Lasec, SA).  Consent was obtained from all 
volunteers.  Whole blood cultures were conducted within 4 hours after blood collection.  All 
methods where performed under sterile conditions.  Stimulated whole blood cultures 
contained 1 volume of 10 µg/ml endotoxin in dimethyl sulfoxide, 10 volumes of blood and 
89 volumes of RPMI-1640 medium (Sigma, USA).  Unstimulated blood contained 1 volume 
DMSO, 10 volumes of blood and 89 volumes of RPMI-1640.  Replicate samples of various 
dilutions of Artemisia afra were transferred to wells of a 96-well plate (2µl/well).  The 
(stimulated or unstimulated) blood (200 µl/well) was added to the Artemisia afra samples and 
incubated at 37 ˚C for 24 hours.  Culture supernatants were then collected and assayed for 
LDH and IL-6.                                                                                                        
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4.2.3  Th1/Th2 activity 
Blood samples were prepared in a manner similar to the preparation using endotoxin (LPS). 
Stimulated whole blood cultures contained 10 volumes of blood and 89 volumes of RPMI-
1640 medium (Sigma, USA) and 1 volume of 1.6mg/ml PHA (Sigma, USA) in RPMI 
(Sigma, USA).  For unstimulated whole blood cultures, no additions were made to the diluted 
blood.  Various concentrations of Artemisia afra extracts (2 µl/well) were added to each well.  
Stimulated or unstimulated blood was added to wells (200 µl/well).  Cultures were incubated 
for 48 hours.  Culture supernatants were then used to perform IL-10 and IFN-γ assays. 
 
4.2.4  Cytotoxicity 
A commercially available chromogenic LDH assay kit (Biovision, USA) was used to 
determine the cytotoxicity of Artemisia afra samples.  Cell culture supernatants were 
collected from blood samples incubated for inflammatory activity.  Samples were transferred 
to a 96-well plate.  For the 100 % toxicity standard a control blood sample (250 µl) received 
2.5 µl of a 10 % volume/volume Triton X 100 solution.  The blood immediately lysed.  An 
aliquot of the lysed blood was diluted in saline at a ratio of 1:10.  The lysed blood sample was 
used as the 100 % cytotoxicity control.  Dilutions of this sample were used to construct a 
standard curve.  The standards were also transferred to the 96-well plate.  LDH substrate was 
added to samples.  Well contents were mixed to produce a homogenous solution by tapping 
the plate.  Absorbance readings were taken at 10 minute intervals at 592 nm.  Between 
readings the plate was incubated in a dark area at ambient temperature.  The cytotoxicity of 
the samples were read off a standard curve constructed using the standards.  
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4.2.5  Cytokine analysis 
 Double antibody sandwhich (DAS) ELISAs (e-Bioscience, Germany) were used to quantify 
cytokine production from Artemisia afra-containing supernatants of the whole blood cultures.  
Nunc maxisorp (NuncTM, Denmark) 96-well plates were used for the assays.  The kit 
contained all diluents and reagents required.  The assay was performed according to 
manufacturer protocol.  Primary antibody (50 µl/well) against the respective cytokine was 
coated onto the plate.  The coat was incubated at 4 ˚C overnight.  Plates were then washed 5 
times with phosphate buffered saline (PBS) containing 0.05 % Tween.  Plates were blocked 
with an assay buffer (100 µl/well) for 1 hour and washed as before.  Cytokine standards and 
samples were added to the wells (50 µl/well).  The plate was incubated on a shaker at 
ambient temperature for 2 hours.  Plates were washed 5 times with wash buffer.  Biotinylated 
secondary (detection) antibody against the respected cytokine was added (50µl/well).  Plates 
were incubated on a shaker at ambient temperature for 1 hour and washed 5 times.  Avidin-
perioxidase conjugate (50 μl/well) was added to the wells and incubated for 30 minutes on a 
shaker at ambient temperature.  The plates were washed 7 times with buffer and substrate was 
added (50 µl/well).  The plates were incubated in a dark area for 15 minutes.  The reaction 
was stopped using 2M H2SO4 as stop solution (50 µl/well).  Plates were then read on a plate 
reader spectrophotometer at 450 nm.  Standard curves for each ELISA plate were generated 
using Excel.  The standard curve was used to determine the amount of cytokines produced by 
the blood cultures. 
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4.2.6  Statistical analysis 
Experiments were all performed thrice, each in triplicate.  Data was statistically analysed 
using one-way ANOVA (P<0.05) and regression analysis.  All data is presented as a mean ± 
standard deviation.   
 
4.3  Results and discussion 
4.3.1  Cytotoxicity of Artemisia afra 
Based on the results of previous studies (Mukinda, 2007), no toxicity of Artemisia afra was 
expected.  Figure 4.1 is a diagrammatical representation of the data obtained for the LDH 
assay.  Data shows that Artemisia afra was significantly toxic (P<0.050) at 5 000 µg/ml, the 
highest concentration tested.  At this concentration, 39.9 % of cellular LDH was leached out 
of cells.  This was much higher than the level found in the control (DMSO) cultures.  At 
lower concentrations Artemisia afra is not cytotoxic.  
 
Figure 4.1 Cytotoxicity of Artemisia afra.  Each point represents the mean and standard deviation of 
triplicate assays.  Data is expressed as a % of the total cellular LDH.  Artemisia afra is significantly 
toxic (P<0.050) at 5000µg/ml. 
 
 
 
 
62 
 
  4.3.2  The anti-inflammatory effect of Artemisia afra 
 
Figure 4.2:   The inflammatory activity of Artemisia afra.  Data represents the mean and 
standard deviation of triplicate assays (n=9).  Results are expressed as a % IL-6 secreted by 
whole blood cultures in comparison to the 0 µg/ml Artemisia afra positive control. 
Significant changes (P<0.001) are indicated (*) at the 1 666 and 5 000 µg/ml concentrations. 
 
IL-6 forms a vital mediator in fever and in the acute phase response of immune activation.  It 
is mainly secreted by macrophages in response to microbial pathogens (Mayor, 2000).  
Results obtained from all the donors were similar and indicate that Artemisia afra has an 
effect on the stimulated whole blood cultures.  At a high concentration (1 666 µg/ml) 
Artemisia afra significantly decreased (P<0.01) the amount of IL-6 produced (16 % 
compared to the control).  This indicates that Artemisia afra could act as an anti-
inflammatory agent.  
Traditional uses of Artemisia afra include colds, influenza, mumps and wounds (Kramer, 
2006, van Wyk and Wink, 2004).  The decrease in IL-6 production induced by Artemisia afra 
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would be beneficial in these conditions as it could bring about symptomatic relief from fever 
caused by infection and also reduce the amount of inflammation at wound sites.  Other 
traditional uses include joint pain and rheumatism (van Wyk and Wink, 2004).  Research has 
indicated that IL-6 levels are increased in rheumatoid arthritis and mechanisms of IL-6-target 
blockade (such as those demonstrated by Artemisia afra) are currently being research as a 
potential treatment (Nishimoto and Norihiro, 2006).   Increased IL-6 levels have been 
associated with an increased risk of intervertebral disc disease (IDD) commonly 
characterized by sciatica (Noponen-Hietala et al., 2005).  Artemsia afra is traditionally used 
as a topical application for back pain and neuralgia (Kramer, 2006).  These results indicate 
that it may have potential in the treatment of these conditions.    
As Artemisia afra is considered a traditional “cure-all”, it is used for a wide variety of 
complaints including diabetes (Mukinda, 2007). Increased IL-6 levels have also associated 
with obesity, non-insulin dependent diabetes mellitus (Herder et al., 2007) and the metastasis 
of cancer (Smith, 2001).  In 2004, Tackey et al. described elevated IL-6 levels as being a key 
factor in the immunopathology of systemic lupus erythematosus (SLE) and may be directly 
responsible for tissue damage.  Through inhibiting IL-6 expression, Artemisia afra may also 
prove to be beneficial in treating these conditions.   
 
4.3.3  The effects of Artemisia afra on humoral immunity 
IL-10 cytokine synthesis by whole blood cultures upon stimulation with PHA was used as a 
biomarker to monitor the humoral immune pathway.   
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Figure 4.3:   The effects of Artemisia afra on humoral immunity.  Data represents the mean 
and standard deviation of triplicate assays (n=9).  Results are expressed as a % IL-10 secreted 
by whole blood cultures in comparison to the 0 µg/ml Artemisia afra control. Significant 
changes (P<0.001) are indicated (*). 
IL-10 acts mainly as an anti-inflammatory cytokine, inhibiting the Th1 pathway.  Due to Th2 
activation by IL-10, B cells and antibody production are activated.  This plays an important 
role in acquired immunity and humoral responses to extracellular bacteria and parasites 
(Kumar and Clark, 1999; Mayor, 2000).  Results show that Artemisia afra significantly 
reduces (P<0.001) the amounts of IL-10 expressed (Figure 4.3).  This supression of the Th2 
pathway may be useful in the treatment of asthma, reducing the activation of granulocytes, 
coinciding with its traditional use in asthma and other allergic conditions.   
Although various digestive complaints are traditionally treated with Artemisia afra, these 
complaints are normally limited to conditions such as gastritis, flatulence, dyspepsia, et 
cetera (van Wyk and Wink, 2004) and not conditions such as food poisoning caused by 
Chlostriduium species, Escherichia coli, Vibrio cholera and other extracellular bacteria.  
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Although this study did not investigate the anti-microbial properties of Artemisia afra against 
these species, results produced still continue to coincide with traditional herbal folk-lore.   
Artemisia species derive their common name (wormwood) from their traditional value in 
eliminating intestinal worms, or helminths.  Basophils are recruited to the infection site from 
the circulation, limiting parasitic spread and aiding in pathogenic excretion from the host 
organism, (hence the “anthelmintic” action traditionally ascribed to Artemisia afra).  
Although basophils are incorporated via the Th2 pathway, their functions are regulated by 
cytokines not included in this study (IL-4, IL-5, IL-9 and IL-13) (Mitre and Nutman, 2006 
and Paul, 2003).  
 
4.3.4  The effect of Artemisia afra on cell mediated immunity   
 
Figure 4.4  The effects of Artemisia afra on cellular immunity.  Data represents the mean and 
standard deviation of triplicate assays (n=9).  Results are expressed as a % IFN-γ secreted by 
whole blood cultures in comparison to the 0 µg/ml Artemisia afra control. Significant 
changes (P<0.001) are indicated (*). 
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IFN-γ plays a regulatory role in both innate and acquired immunity.  By encouraging Th1 
pathways, it results in increased macrophage activity and increased anti-viral activity via NK 
cell activity (Mayor, 2000).  Because of this increase in cell-mediated immunity, it plays a 
key role in host defences against intracellular bacteria and viruses.   
Results indicate a significant decrease in cytokine production (P<0.001) at the 1 666 µg/ml 
concentration (32.7 % compared to the control).  Artemisia afra is commonly used for 
various viral infections such as colds, influenza and mumps, although all assays performed 
indicate a decrease in anti-viral activity.  Malaria is caused by Plasmodium malariae, 
Plasmodium vivax, Plasmodium ovale or Plasmodium falciparum.  It is endemic in Africa 
and is one of the most common conditions traditionally treated using Artemisia afra (Beers, 
2006;  Mukinda, 2007).  The data obtained from these assays shows that IFN-γ was not 
significanly increased, as would normally be necessary in cases of intracellular parasitic 
invasion.  
The study did not, however, investigate for any direct anti-microbial action against 
Plasmodium species nor any viral pathogens and it may possibly have an effect on the 
microbe itself.  As confirmed under the inflammatory section of this study,  using Artemisia 
afra may provide symptomatic benefit to those suffering from malaria and viral infections by 
acting as an anti-pyretic and decreasing fever. Fever is one of the classical symptoms of 
numerous infections, including infuenza and malaria (Beers, 2006).   
Scientific literature focuses mainly on a different species of Artemisia, Artemsia annua 
(commonly known as Chinese wormwood or sweet wormwood) as having anti-malarial 
effects.  The main pharmacological active compound in this species has been found to be 
artemisinin, a sesquiterpene lactone.  Although Artemsia afra does contain sesquiterpene 
lactones, it does not contain artemisinin (van Wyk and Wink, 2004).   
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4.4  Conclusion 
Artemisia afra is one of South Africa‟s most common herbs traditionally used as a medicine 
to treat a wide variety of complaints ranging from bacterial, viral and parasitic infections.    
Results show that Artemisia afra decreases the production of IL-10.  This supression of the 
Th2 pathway may be useful in the treatment of asthma, reducing the activation of 
granulocytes, coinciding with its traditional use in asthma and other allergic conditions.   
Results are also cohesive with traditional uses of the plant regarding inflammatory pathways.  
Data shows that Artemisia afra acts as an inflammation inhibitor. At higher concentrations, 
the amount of IL-6 is decreased.  This demonstrates a potential ability to reduce the effects of 
auto-immune conditions such as RA and SLE.  Conditions such as arteriosclerosis, rheumatic 
pains, sciatica, neoplastic metastasis and non-insulin dependant diabetes mellitus have all 
been associated with abnormally high levels of IL-6.  Artemisia afra could play a promising 
role in the treatment and prevention of these diseases.    Fever is associated with numerous 
bacterial, viral, and parasitic infections, such as influenza, colds, mumps and malaria 
(Holmes, 2007).  In these conditions, symptomatic relief could be brought about by using 
Artemisia afra to decrease the fever.  Further studies will be needed to better explore these 
avenues of immunoregulation, as well as the antimicrobial effects of Artemisia afra on 
parasitic and viral pathogens and the long term effects of the herb on the immune and other 
physiological systems. 
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Chapter 5:  Summary, Conclusion and Recommendations 
5.1  Summary 
Cytokines play an important role in inducing and balancing immune defence mechanisms.  
IL-6 is responsible for regulating inflammation.  It induces initial acute phase inflammation 
via innate processes.  Via Th1 pathways, cellular immune processes result in NK cells up 
regulating IFN-γ production, vital to eliminating viral and intracellular bacterial infections.  
Th2 pathway activation results in T regulatory cells producing IL-10.  This induces B cell 
proliferation and antibody production.  These humoral responses are vital in eliminating 
extracellular and parasitic infection.  It also plays a key role in hypersensitivity reactions 
against allergens (Clark, 2009;  Mayor, 2000 and Paul, 2003).   
Because of these key roles, these three cytokines were used as biomarkers in an in vitro study 
examining the immune regulating effects of the indigenous herb, Artemisia afra.  IL-6 was 
used as a biomarker to indicate inflammatory activity.  IFN-γ was used to indicate cellular 
immune activity, while IL-10 was used to indicate humoral activity.  Herbal forms of 
medication are becoming increasingly popular within the general population, and medical 
practitioners are not well-equipped to address this growing popularity.  Unpleasant side 
effects and potentially harmful adverse effects become common when the herb is taken 
incorrectly, or when it is taken together with certain pharmaceutical medications (Rai, 2005).   
Limited literature exists regarding the biological and immune activities of herbs, and even 
less so regarding local herbs.  Past studies involving indigenous herbs have focused on 
pharmacokinetic effects using HPLC and GC-MS.  Antimicrobial studies have also been 
done on numerous South African species.  No previous studies have been done on Artemisia 
afra, examining its effects on the immune system, despite its wide range of traditional 
indications ranging from various pathogenic infections to inflammatory and auto-immune 
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conditions.  A quick and effective method of screening indigenous herbs for immune 
regulating effects is essential.  The aim of this study was to determine if immunomodulating 
activities of herbs could be effectively validated using in vitro methods, and to determine the 
effects of Artemisia afra on inflammation and immune regulation.   
Results were consistent with traditional uses of Artemisia afra such as fever, asthma and 
various conditions requiring a decrease in the amount of IL-6 produced such as sciatica, 
diabetes mellitus and rheumatoid arthritis.  Results also coincided with traditional uses 
involving bacterial, viral and parasitic infections such as sore throats, influenza and malaria, 
where decreasing fever would be beneficial and bring about symptomatic relief.   
 
5.2  Conclusion 
Herbal medications can be effectively screened for immune regulating activity in vitro using 
whole blood cultures.  Artemisia afra is cytotoxic at high concentrations.  It appears to be 
beneficial in some conditions traditionally treated with the herb, such as diabetes and joint 
pain.  It does not, however, appear to directly stimulate the immune system to fight off 
bacterial, viral and parasitic infections.   
It demonstrates an inhibitory effect on the inflammatory process, down-regulating IL-6 
production at higher concentrations.  This could be potentially useful in treating auto-immune 
conditions such as rheumatoid arthritis and systemic lupus erythematosus and other 
conditions such as diabetes mellitus, cancer metastases and arteriosclerosis, where IL-6 levels 
are excessively high.  In terms of cellular and humoral immune processes, results indicate 
that the herb acts mainly as an immune suppressant, decreasing the amounts of IL-10 and 
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IFN-γ produced.  This coincides with previous studies done on other Artemisia species.  It 
may also be potentially valuable in the treatment of certain allergies. 
 
5.3  Recommendations 
Further investigation is needed to help validate the findings produced by this study, including 
that of in vivo studies and more extensive studies investigating the anti-microbial effects of 
Artemisia afra against pathogens such as Plasmodium malariae, Influenza species and 
various helminths.  Similar studies should also be done evaluating other indigenous herbs.  
When preparing the herb sample, extracts closer to the traditional dosage form and 
concentration represent the ideal.  Water extractions are more often used.  Although tinctures 
are traditionally used, these are normally made using a low-medium percentage of alcohol.   
The general public and practitioners of Western medicine need to be more educated regarding 
the correct use and physiological effects of herbs.  This will lead to a better working 
knowledge of herbs, enabling them to be used more effectively and reducing the changes of 
undesired adverse effects.  Scientists and traditional herbal practitioners should regularly 
communicate in terms of traditional uses and modern findings (such as cytotoxic effects at 
certain concentrations) as both populations have both much to learn and much to offer the 
other.  
   
 
 
 
 
 
